5 news items
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
ATXI
FBIO
15 May 24
proceeds.R&D Expenses: Research and development expenses for the first quarter of 2024 were $2.4
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
ATXI
FBIO
25 Mar 24
capital expenditures to expand our research and development and manufacturing capabilities; expectations for generating revenue or becoming profitable
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
ATXI
FBIO
18 Mar 24
: Research and development expenses for the full year 2023 were $6.1 million, compared to $2.7 million in 2022. Additionally, there was $4.2 million in expense
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
ATXI
FBIO
15 Mar 24
or in-license; our use of clinical research centers and other contractors; expectations for incurring capital expenditures to expand our research
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
ATXI
FBIO
11 Mar 24
research centers and other contractors; expectations for incurring capital expenditures to expand our research and development and manufacturing
- Prev
- 1
- Next